 Patient outcome analysis will be primarily based on the proportion of disease-free patients after 9 months follow-up cost-effectiveness analysis. As a secondary analysis a cost-utility analysis will be carried out. For this purpose the EQ-5D instrument will be used to estimate utilities for each patient at the different measurement moments. In addition, a generic SF-36 and a disease-specific EORTC QLQ-C30 descriptive health-related quality of life questionnaire will be applied. 